Browse
Explore conditions, clinical trials, and the organisations running them.
Never miss a new study
Get alerted when new trials match your condition
Sign up free to track the conditions you care about and get a personal digest when new trials appear.
By submitting, you agree to our Terms of use
116076 trials found · Page 603 of 5804
-
Fat-Derived stem cells injected into brain during surgery to fight glioblastoma
Disease control Recruiting nowThis phase I trial tests the safety, side effects, and best dose of allogenic adipose-derived mesenchymal stem cells (AMSCs) in treating patients with glioblastoma or astrocytoma that has come back (recurrent) who are undergoing brain surgery (craniotomy). Glioblastoma is the mos…
Phase: PHASE1 • Sponsor: Mayo Clinic • Aim: Disease control
Last updated Jun 27, 2026 12:03 UTC
-
Could a headset at home lift depression when pills fail?
Symptom relief CompletedDepression has a yearly prevalence superior to 5%, but a 30% of patients cannot benefit of pharmacological treatment, resulting resistant to it. Transcranial direct current stimulation, due to its reduced invasiveness and easy administration showed to be a useful technique to tr…
Phase: NA • Sponsor: Institut Guttmann • Aim: Symptom relief
Last updated Jul 04, 2026 00:00 UTC
-
Gene therapy for hemophilia b: does it last? new study tracks 500 patients over years.
Disease control Recruiting nowThis observational, post-authorization, long-term follow-up study aims to investigate the short and long-term effectiveness and safety of HEMGENIX in patients with hemophilia B. The study will also include a cohort of patients with hemophilia B treated with FIX prophylaxis to ena…
Sponsor: CSL Behring • Aim: Disease control
Last updated Jun 27, 2026 09:06 UTC
-
Experimental gene injection aims to halt rare childhood blindness
Disease control Recruiting nowThe goals of this clinical trial are assess the natural course of LCA5-IRD over 6 months and to evaluate the safety and preliminary efficacy of subretinal gene therapy with OPGx-001 in patients with inherited retinal degeneration due to biallelic mutations in the LCA5 gene. Fundi…
Phase: PHASE1, PHASE2 • Sponsor: Opus Genetics, Inc • Aim: Disease control
Last updated Jun 27, 2026 09:06 UTC
-
New combo therapy aims to control multiple myeloma after first return
Disease control Recruiting nowAt present, there is no prospective study on the treatment of first-relapsed multiple myeloma with daratumumab plus pomalidomide and dexamethasone (Dara-Pd). A prospective, multicenter, open, non-interventional, observational clinical study to evaluate the efficacy and safety of …
Sponsor: FengYan Jin • Aim: Disease control
Last updated Jun 27, 2026 12:03 UTC
-
Can a surprise twist help erase trauma? new PTSD trial investigates
Symptom relief Recruiting nowThe proposed R21 project will attempt to further develop a novel intervention for posttraumatic stress symptoms inspired by the science of memory reconsolidation. Work in normal humans has shown that when a stable, consolidated memory is reactivated (i.e., retrieved) under approp…
Phase: PHASE4 • Sponsor: Massachusetts General Hospital • Aim: Symptom relief
Last updated Jun 27, 2026 12:28 UTC
-
New pill vs. standard shot: which works better for Tough-to-Treat rheumatoid arthritis?
Disease control OngoingRheumatoid Arthritis (RA) is a chronic inflammatory disease causing pain, stiffness, swelling and loss of joint function. This study will assess how safe and effective upadacitinib is in treating RA when compared to adalimumab in adult participants with inadequate response or int…
Phase: PHASE3 • Sponsor: AbbVie • Aim: Disease control
Last updated Jun 27, 2026 08:10 UTC
-
New drug aims to cut fractures in kids with brittle bones
Disease control OngoingThe primary objective of the study is to evaluate the effect of setrusumab vs intravenous bisphosphonates (IV-BP) on reduction in fracture rate, including morphometric vertebral fractures in pediatric participants.
Phase: PHASE3 • Sponsor: Ultragenyx Pharmaceutical Inc • Aim: Disease control
Last updated Jun 27, 2026 09:07 UTC
-
Lung cancer patients may soon get immunotherapy as a quick shot
Disease control OngoingThis study is to assess the pharmacokinetics (PK) and safety of SC pembrolizumab (+) berahyaluronidase alfa vs intravenous (IV) pembrolizumab, administered with chemotherapy in first line treatment of adult Japanese participants with metastatic non-small cell lung cancer. The pri…
Phase: PHASE3 • Sponsor: Merck Sharp & Dohme LLC • Aim: Disease control
Last updated Jun 27, 2026 07:57 UTC
-
New Three-Drug cocktail takes on tough melanoma
Disease control TerminatedThe purpose of this study is to learn about the effects of 3 study medicines (encorafenib, binimetinib, pembrolizumab) compared to 2 study medicines (ipilimumab and nivolumab) given for the treatment of melanoma. Melanoma is a type of cancer that starts in the cells that give co…
Phase: PHASE2 • Sponsor: Pfizer • Aim: Disease control
Last updated Jun 27, 2026 11:00 UTC
-
Gene therapy could restore saliva flow in dry mouth sufferers
Disease control OngoingThis study will assess the efficacy and safety of bilateral intra-parotid administration of AAV2-hAQP1 in adults with Grade 2 or Grade 3 radiation-induced late xerostomia.
Phase: PHASE2 • Sponsor: MeiraGTx, LLC • Aim: Disease control
Last updated Jul 26, 2026 00:00 UTC
-
Blood test could match resistant breast cancer to best drug
Disease control Recruiting nowThis study is being done to answer the following question: Can testing breast cancer for DNA abnormalities or "biomarkers" help predict which patients are most likely to be helped by certain treatments? The pre-study screening is being done to test a sample of blood (or tumour ti…
Phase: PHASE2 • Sponsor: Canadian Cancer Trials Group • Aim: Disease control
Last updated Jun 27, 2026 12:31 UTC
-
Tai-Chi and lactulose combo tested to stop falls in liver patients
Prevention CompletedThis multicenter trial is being conducted to determine if sequential lactulose and Tele (virtual) Tai-Chi reduces the rate of injurious fall, non-injurious falls, incident overt Hepatic Encephalopathy (HE), and death or liver transplant over 24 weeks. Participants that are enrol…
Phase: PHASE3 • Sponsor: University of Michigan • Aim: Prevention
Last updated Jun 26, 2026 15:25 UTC
-
New dosing strategy for MS drug ublituximab under study in 800-Patient trial
Disease control Recruiting nowThe primary purpose of this phase 3b study is to assess the efficacy of a modified regimen of ublituximab in participants with relapsing multiple sclerosis (RMS) as measured by T1 Gadolinium (Gd)-enhancing lesions in Part A; PK in Part B along with efficacy of ublituximab as meas…
Phase: PHASE3 • Sponsor: TG Therapeutics, Inc. • Aim: Disease control
Last updated Jul 19, 2026 00:00 UTC
-
Itch-Busting cream shows promise for painful skin bumps
Symptom relief CompletedThe purpose of this study is to evaluate the safety and tolerability of Ruxolitinib cream in participants with Prurigo Nodularis (PN).
Phase: PHASE3 • Sponsor: Incyte Corporation • Aim: Symptom relief
Last updated Jun 27, 2026 08:05 UTC
-
Could a common diabetes pill prevent heart failure after a heart attack?
Disease control Recruiting nowRecent clinical trials have proven the cardiovascular benefits of new medications for patients with heart failure with reduced ejection fraction (HFrEF), especially sodium-glucose co-transporter 2 (SGLT2) inhibitors. There are no existing randomized clinical trials evaluating the…
Phase: PHASE3 • Sponsor: Assistance Publique - Hôpitaux de Paris • Aim: Disease control
Last updated Jun 27, 2026 08:05 UTC
-
Could two old drugs boost chemo for pancreatic cancer?
Disease control Recruiting nowThis is a proof-of-concept, Open label, randomized, multicentric, superiority phase-2 study.
Phase: PHASE2 • Sponsor: National Cancer Institute, Naples • Aim: Disease control
Last updated Jun 27, 2026 12:07 UTC
-
New drug duo takes on tough liver cancers
Disease control OngoingThe goal of this clinical trial is to learn about advanced liver and bile duct cancers. The main question it aims to answer is: If the combination of Domvanalimab and Zimberelimab are effective in treating advanced hepatobiliary cancers that have failed prior treatment.
Phase: PHASE2 • Sponsor: University of Texas Southwestern Medical Center • Aim: Disease control
Last updated Jul 04, 2026 00:00 UTC
-
Can booster drugs keep lymphoma in check after CAR t therapy?
Disease control Recruiting nowThis phase II trial tests whether mosunetuzumab and/or polatuzumab vedotin helps benefit patients who have received chemotherapy (fludarabine and cyclophosphamide) followed by chimeric antigen receptor (CAR) T-cell therapy (tisagenlecleucel, axicabtagene ciloleucel, or lisocabtag…
Phase: PHASE2 • Sponsor: SWOG Cancer Research Network • Aim: Disease control
Last updated Jun 27, 2026 09:02 UTC
-
Hope for rare skin disease: new drug shows promise in trial
Disease control TerminatedThis study is open to people with a skin disease called Netherton syndrome (NS). People can join the study if they are 12 years or older. The purpose of this study is to find out whether a medicine called spesolimab helps people with NS. Participants are divided into a spesolima…
Phase: PHASE2, PHASE3 • Sponsor: Boehringer Ingelheim • Aim: Disease control
Last updated Jun 27, 2026 11:00 UTC